NEWS AND UPDATES

December 2023

Our work on SSADH deficiency was featured in a poster highlight session in the American Epilepsy Society Annual Meeting 

Amber Freed joins Galibra Neuroscience as Chief Development Officer.

Galibra Neuroscience obtains Option License Agreement from Boston Children’s Hospital for developing AAV-mediated gene replacement therapy for SSADH deficiency.

Dr Phillip Pearl joins Galibra Neuroscience as Clinical Study Consultant.

2023

Galibra Neuroscience was founded by Drs Alexander Rotenberg and Henry Lee.

Scroll to Top